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SUPPLEMENTARY METHODS
Construction of Dual-Affinity Tag Vector
To assemble the HtS (6His-2tev-2StrepII-CCPGCC) tag element, we annealed the HtS sense and antisense oligonucleotides followed by PCR amplification with HtS forward and reverse primers. To generate the tetracycline-inducible p31-N-HtS vector (YW547), the PCR product was digested with BbsI/XhoI and ligated into the BbsI/XhoI sites of pTRex-DEST31 (Invitrogen, Carlsbad, CA, USA) in place of the 6×His tag. The same strategy was used to create p40-C-StH (YW542) vector with StH (CCPGCC2StrepII-2tev-6His) tag, except that the PCR product was digested with BstBI/ EcoRV and cloned into BstBI/PmeI sites of pDEST40 (Invitrogen) in place of the V5-6×His tags. For the assembly of the StP (CCPGCC-2StrepII-2tev-2ProA) element, we first generated the center portion of the tag by annealing the StP sense and antisense oligonucleotides. We then used the annealed oligonucleotide as a template to obtain a full-length StP element by three rounds of PCR amplification with three pairs of StP forward and reverse primers. To create the p40-C-StP (YW539) vector, the PCR product was digested with BstBI/EcoRV and ligated into BstBI/ PmeI sites of pDEST40. The same cloning strategy was used to create the p31-N-PtS (YW548) vector, except that the PCR product was digested with BbsI/XhoI, and ligated into the BbsI/ XhoI site of pTREx-DEST31 in place of the 6×His tag. To create p40-CHAtP vector carrying 3HA-2tev-2ProA tag, the CCPGCC-StrepII sequences of p40-C-StP were removed by BstB1/ HindIII and subsequently filled with Klenow and swapped with HA tag derived from pcDNA3-HA by blunt ligation. Sequences of the annealing oligonucleotides and primers used for the dual-affinity tag constructions will be provided upon request. Refer to Figure 1A for sequence details.
Human telomeric repeat binding factor 2 (TRF2) open reading frame cDNA was amplified by PCR from a pcDNA-flag-hTRF2 vector with primers specific for the TRF2 coding sequence, flanked by either attB1 or attB2 sequences (Gateway ® -compatible), as previously described (1) . Primers are as follows: 5′-GGGGA CAAGTTTGTACAAAAAAGCAGGC TTGGCTGGTGGTGGTGGTT-3′ and 5′-GGGGACCACTTTGTACAAGAA AGCTGGGTCTTAGTTCATGCCAA GTCTTT-3′. The PCR products were cloned into the Gateway pDONR221 donor vector (Invitrogen) through the BP reaction (2) and were compatible for both N′ and C′ tagging. To create TRF2 dual-affinity tag constructs, TRF2 was subsequently transferred from pDONR221-TRF2 into our newly constructed Gateway-compatible destination vectors (p31-N-HtS, p31-N-PtS, p40-C-StP, p40-C-StH and p40-CHAtP) via an LR reaction as described by the manufacturer. His-tagged TRF2 bacterial expression vector was created through LR recombination between pDONR221-TRF2 and pDEST17 (Invitrogen).
Cell Lines and Transfection
For transient expression, baitcomplex purification, and mass spectrometry (MS) analysis, dual-tag TRF2 fusion constructs ( Figure 1A ) were transfected into HEK 293T cells (ATCC, Manassas, VA, USA) using Lipofectamine™ PLUS ® (Invitrogen) or FuGENE ® 6 (Roche, Diagnostics, Indianapolis, IN, USA) following the manufacturer's protocols. To establish stable cell lines carrying tetracyclineregulatable N-HtS-TRF2, also for dualpurification and MS analysis, HEK 293T cells were first transfected with pcDNA™6/TR (Invitrogen) carrying a tetracycline-repressor followed by selection with 5 μg/mL Blasticidin-S (Invitrogen). Antibiotic-resistant clones were then co-transfected with the dual-tag construct (N-HtS-TRF2) and pBabe-puro (for initial fast-acting selection; a kind gift from Dr. Gerard Evans), and stable clones were established with further selection (3 μg/mL puromycin, 800 μg/mL G418, and 5 μg/mL blasticidin). Before dual-tag purification, N-HtS-TRF2 stable clones were induced with 3 μg/mL tetracycline for 24 h and harvested.
For TRF2-C-StH/telomere co-localization experiments ( Figure 1D ), U2OS cells (ATCC) were grown on coverslips to approximately 30% confluency, transfected with TRF2-C-StH by FuGENE 6, incubated for 24 h, and stained as described in the following sections.
Cell Lysis
Total protein extract was obtained by one of three lysis procedures: freeze/ thaw-based whole-cell lysis (WCL), detergent-based WCL, or nuclear lysis (NL); the former of which provides a more concentrated whole-cell lysate that improves bait capture efficiency. The details for each lysis protocol are as follows.
Freeze/thaw whole-cell lysis. As previously described (3,4) but modified. Cells were pelleted at 200× Benchmarks g, and the packed-cell volume (PCV) was noted. Cells were resuspended in 2× PCV of BF3-HisFT [50 mM Tris, 150 mM NaCl, 50 mM NaH 2 PO 4 , 10 mM imidazole, 0.1% Nonidet™-P40 (NP40), 10% glycerol, pH 8.0, with 10 mM fresh β-mercaptoethanol], Roche protease inhibitor cocktail, and 50 μg/ mL Avidin). Cells were incubated on ice for 10 min, subjected to three freeze/ thaw cycles using dry ice/ethanol and 4°C water baths, and passed through a 25-gauge needle between cycles. Lysate was then centrifuged at 21,000× g for 30 min. Supernatant was subsequently placed atop beads specific to the first purification (see below).
Detergent-based whole-cell lysis. Buffer 3 [BF3: 50 mM Tris, 150 mM NaCl, 0.1% NP40, 1 mM dithiothreitol (DTT), protease inhibitor cocktail, adjusted to pH 8.0] or BF3-His (same as above plus 50 mM NaH 2 PO 4 , 20 mM imidazole, and 10 mM β-mercaptoethanol instead of DTT) was added to the cell pellet (0.5-1 mL/10 cm 2 plate of 293T cells) and incubated on ice for 30 min. Lysate was then passed through a 25-gauge syringe and centrifuged at 4000× g for 5 min. Supernatant was transferred to microfuge tubes and centrifuged at 21,000× g for 30 min. Supernatant was then placed atop beads specific to the first purification (see below).
Nuclear lysis. Two volumes of Buffer A [10 mM HEPES, pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, a Complete™ Mini Protease Inhibitor tablet (Roche)] were added to the cell pellet and incubated on ice for 15 min. Solution was adjusted to 0.6% NP40, vortex mixed briefly, and immediately centrifuged at 4000× g for 45 s. The supernatant (cytoplasmic fraction) was removed, and 1 mL buffer C-His (20 mM HEPES, pH 7.9, 400 mM NaCl, 20 mM imidazole, 1 mM DTT, Complete Protease Inhibitor Cocktail) or buffer C (buffer C-His minus the imidazole, plus 0.1 mM EDTA and 0.1 mM EGTA) was immediately added to the pelleted nuclei. Nuclei were resuspended, and the lysates were passed through a 25-gauge syringe needle followed by incubation on ice for 30 min. Crude nuclear lysate was then centrifuged at 4000× g for 45 s, and the supernatant (nuclear fraction) was collected. The nuclear fraction was subsequently centrifuged at 21,000× g for 30 min at 4°C, and the supernatant was immediately placed atop beads specific to the first purification (see the section entitled Dual-Tag Purification and MS Sample Preparation).
Note: If the dual-affinity tag contained a StrepII component, avidin was added to the lysate at a final concentration of 50 μg/mL, which blocks biotinylated proteins in the lysate from being nonspecifically pulled down by the Strep-Tactin beads.
Dual-Tag Purification and MS Sample Preparation
All five TRF2 constructs ( Figure  1A ) were introduced into 293T cells (or 293T T-REx to generate N-HtS-TRF2 stable line), expressed, and lysates were prepared as described above. Beads specific to the outer affinity tag [Ni-NTA (Qiagen, Valencia, CA, USA) for His-tag, immunoglobulin G (IgG) Sepharose™ 6 Fast Flow (GE Healthcare, Piscataway, NJ, USA) for ProA-tag] were equilibrated with lysis buffer and incubated with lysate (200 μL solid beads per 1.5 mL lysate) for 2 h at 4°C with agitation. Samples were transferred to an empty poly-prep column (Bio-Rad, Hercules, CA, USA), and the beads were washed with three 10-mL additions of wash buffer (Histag: 50 mM Tris, 50 mM NaH 2 PO 4 , 150 mM NaCl, 20 mM imidazole, 1 mM DTT, 0.1% NP40, pH 8.0; ProAtag: without imidazole) and one 10-mL addition of TEV cleavage buffer (TCB: 50 mM Tris, 150 mM NaCl, 0.5 mM EDTA, 0.1% NP40, 1 mM DTT, pH 8.0). Beads, resuspended in 1 mL TCB, were then transferred to another microfuge tube and treated with 50 U AcTEV™ protease (Invitrogen) for 1 h at room temperature with agitation. The supernatant was collected, placed atop 200 μL beads specific to the inner affinity tag [Strep-Tactin beads (StrepII-tag ® ; IBA, St. Louis, MO, USA), HA antibody conjugated to ProA beads for HA-tag], and incubated for 2 h at 4°C with agitation. The supernatant was removed, and the beads were washed with three 1-mL additions of wash buffer (100 mM Tris, pH 8.0, 150 mM NaCl, 1 mM EDTA, 1 mM DTT). The doubly purified bait-complex was recovered by three 500-μL additions of elution buffer [StrepII-tag: 100 mM Tris, pH 8.0, 150 mM NaCl, 1 mM EDTA, 1 mM DTT, 20 mM desthiobiotin (IBA); HA-tag: 80% acetonitrile, 0.025% formic acid) with 5 min of agitation between each elution. Samples were collected at each step and analyzed by Western blot analysis (mouse anti-Strep-tag; Qiagen) to monitor purification progress and yield. For MS analysis, samples were prepared as originally described by Link et al. (5) with modifications (6).
Two-Dimensional MudPIT Liquid Chromatography and Tandem MS
The resultant peptides, acidified to 5% formic acid, were loaded onto the back column of a 3-phase multidimensional protein identification technology (MudPIT) setup using a pressure cell as previously described (5, 6) . Briefly, a 100 μm inner diameter (i.d.) capillary back column containing a C18 reverse phase [RP; Aqua, 5-μm particle, 200 Å pore (Phenomenex, Torrance, CA, USA)] behind a strong cation exchange phase (SCX; Luna, 5-μm particle, 100 Å pore [Phenomenex]) was attached to a 100 μm i.d resolving front column/ nanospray tip packed with C18 RP (Jupiter, 5-μm particle, 300 Å pore [Phenomenex] ). Once situated on the nanospray source and equilibrated, five liquid chromatography tandem mass spectrometry (LC-MS/MS) cycles were performed per sample. The first cycle consisted of an organic gradient from 100% Solvent A (95% water, 5% acetonitrile, 0.1% formic acid) to 100% Solvent B (30% water, 70% acetonitrile, 0.1% formic acid) over 100 min. In cycles 2-5, a salt pulse of 400 mM ammonium acetate (10%, 25%, 60%, 100%, respectively) was followed by an organic gradient (0% to 100% Solvent B over 100 min). In all cycles, the effluent was analyzed by MS/MS.
The chromatography was performed using an UltiMate™ LC pump (LC Packings, Dionex, Sunnyvale, CA, USA), and the data was collected by a liquid quadrupole ion trap (LTQ) using an LXQ™ linear ion trap mass spectrometer. (Thermo Fisher Scientific, Waltham, MA, USA) operating in data-dependent mode.
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Data Analysis
MS/MS spectra were analyzed by DBDigger (7) using human International Protein Index (IPI) database version 3.05. The search algorithm was instructed to consider peptides containing alkylated cysteines (+57 Da). Enzyme specificity for the search was fully tryptic and allowed for missed cleavages. The search algorithm was instructed to allow a precursor mass error of 3.0 and a fragment mass error of 0.5. DTASelect was used to filter and organize the search results; Contrast was used to control-filter the TRF2 data sets (see below) to differentiate between putative specific and nonspecific interacting proteins (8) . Peptide/ protein identification acceptance was contingent upon the following criteria: XCorr filter levels were required to be ≥23.75832, ≥28.06619, or ≥43.63964, for singly, doubly, and triply charged ions, respectively, allowing for an approximated 5% false discovery rate at the peptide level; DeltCN was required to be ≥0.08 and a minimum of two peptides per locus was required per protein identification that did not appear in the control data set (generated by performing several control pulldowns that identified proteins that nonspecifically bind to the affinity beads, the tag itself, and to proteins in general).
Lumio Visualization of TRF2 Fusion Proteins
U2OS cells were grown on coverslips, transfected with TRF2-C-StH by FuGENE 6 , incubated for 24-h, and stained with Lumio™ (Invitrogen) as previously described (9) with slight modifications. Briefly, 1 μL 2 mM Lumio Green was preincubated with 1 μL 25 mM EDT and 1 μL dimethyl sulfoxide (DMSO) for 15 min in the dark. The labeling solution was then diluted with 200 μL phosphatebuffered saline (PBS) and incubated for 10 min in the dark. Cells were washed with PBS and immersed in 1.8 mL prewarmed PBS. The labeling solution was then applied and incubated for 30 min at 37°C. Cells were washed once with PBS and three times for 10 min each with PBS containing 350 μM EDT. TRF2-C-StH was visualized in live cells using a immunofluorescence microscope (Carl Zeiss MicroImaging, Thornwood, NY, USA) and acquired with a charge-coupled device camera using the Adobe ® Photoshop ® software. Following live cell imaging, cells were fixed with 2% paraformaldehyde and labeled by fluoresence in situ hybridization (FISH) using a Cy™3-labeled telomeric probe as previously described (10) and visualized.
To visualize the TRF2 fusions by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), 40 μg lysate were processed using Invitrogen's Lumio Green Detection kit according to the manufacturer's instructions, separated on a 10% polyacrylamide gel, and visualized with a UV transluminator.
His-Tagged TRF2 Purification and Dot Blotting Analysis
For the production of His-tagged human TRF2, BL21 CodonPlus ® cells (Stratagene, La Jolla, CA, USA) carrying pDEST17-TRF2 were grown at 30°C to approximately 0.6 of absorbance (A) 600 and induced for 4.5 h by 1 mM (isopropyl-β-dthiogalactopyranoside (IPTG). Cells were harvested and resuspended in His binding buffer (20 mM Tris-HCl, pH 7.9, 0.5 M NaCl, 5 mM imidazole, Roche protease inhibitor cocktail) and lysed by sonication. The lysate was then incubated with Ni-NTA beads (Qiagen) and washed with His-wash buffer (20 mM Tris-HCl, pH 7.9, 0.5 M NaCl, 60 mM imidazole). Bound His-TRF2 was then eluted in Hiselution buffer (Tris-HCl, pH 7.9, 0.5 M NaCl, 1 M imidazole). Purity of the purified His-TRF2 was determined by SDS-PAGE analysis, and the concentration was obtained using Bradford Assay according to the manufacturer's instruction.
For the dot blot analysis, purified recombinant His-TRF2 and N-HtS-TRF2 whole-cell lysate from the pulldown were serially diluted and spotted on a nitrocellulose membrane. The membrane was then probed with rabbit anti-His tag antibody (H-15; Upstate, Millipore, Billerica, MA, USA), followed by donkey anti-rabbithorseradish peroxidase (HRP), and developed with ECL reagent (Pierce Biotechnology, Rockford, IL, USA). To obtain the concentration of NHtS-TRF2, spots were analyzed and compared with spots of known concentration of His-TRF2 by densitometry using ImageJ's Gel Analysis Plugin (National Institutes of Health).
